GLP-1 Receptor Agonists and Cardiovascular Disease: SELECT Trial Analysis, Direct Cardiomyocyte Mechanisms, BP Reduction, and Testosterone-Vascular Interactions

The critical methodological feature of SELECT — mandatory exclusion of T2DM — removes glycemic variability reduction, postprandial hyperglycemia attenuation, and HbA1c-mediated atherogenesis reduction as confounding explanations for MACE reduction. The residual HR 0.80 must be attributed to non-glycemic mechanisms. Time-to-event analysis in SELECT revealed Kaplan-Meier curve separation commencing at approximately 4-6 months — earlier than the magnitude of weight loss at that timepoint (mean -5.2% at 6 months) would predict based on epidemiological weight-MACE relationship estimates (approximately 1% MACE risk per 1% weight reduction). This temporal disjunction, combined with the non-diabetic mechanistic exclusion, provides strong inferential evidence for direct pharmacological cardiovascular effects independent of the adipose-reduction phenotype. The atrial fibrillation signal in SELECT (exploratory analysis: HR 0.79 for AFib-related hospitalizations) is particularly mechanistically interesting — weight loss reduces left atrial volume and pressure, but the magnitude of AFib reduction requires explanation beyond structural remodeling alone, implicating GLP-1R signaling on sinoatrial nodal cells and atrial cardiomyocytes where GLP-1R expression has been confirmed by RNA-seq datasets.

GLP-1R is expressed on ventricular cardiomyocytes, where agonism generates cAMP via Gs protein coupling, activating PKA and subsequently CREB-mediated transcriptional changes. The cardiometabolic relevance centers on substrate utilization during ischemia. At rest, cardiomyocytes preferentially oxidize fatty acids (60-70% of energy substrate). During ischemia — when oxygen delivery is insufficient for fatty acid beta-oxidation, which requires more oxygen per ATP generated than glucose oxidation — the myocardium must shift to glucose. GLP-1R agonism promotes this metabolic flexibility: GLP-1R/cAMP signaling upregulates GLUT1 and GLUT4 translocation, increases hexokinase activity, and suppresses pyruvate dehydrogenase kinase 4 (PDK4), preserving pyruvate entry into the TCA cycle. In the HEART trial (GLP-1 infusion in non-diabetic patients undergoing CABG), GLP-1 reduced perioperative cardiac events and improved LV function recovery — direct evidence of intraoperative cardioprotection. Separately, GLP-1R agonism activates cardioprotective PI3K/Akt survival signaling in cardiomyocytes, reducing apoptosis during ischemia-reperfusion injury in preclinical models (NF-κB suppression, BAX/BCL-2 ratio improvement, cytochrome c release reduction). These are the cellular mechanisms underlying the early MACE curve separation in SELECT.

GLP-1R on proximal tubular epithelial cells of the kidney inhibits the Na+/H+ exchanger 3 (NHE3) via cAMP/PKA phosphorylation — the same transporter targeted by SGLT2 inhibitors and thiazide diuretics through different mechanisms. NHE3 inhibition reduces sodium reabsorption in the proximal tubule, producing natriuresis and volume contraction. This mechanism accounts for the consistent 4-6 mmHg systolic BP reduction seen across GLP-1 trials, including in normotensive participants — a magnitude comparable to low-dose ACE inhibitor monotherapy. The endothelial mechanism is distinct and additive: GLP-1R on vascular endothelial cells activates eNOS (endothelial nitric oxide synthase) via PI3K/Akt-mediated Ser1177 phosphorylation, increasing NO bioavailability. Endothelial NO reduces vascular smooth muscle tone (vasodilation), inhibits platelet aggregation, reduces LDL oxidation in the subendothelial space, and suppresses VCAM-1 and ICAM-1 expression — the adhesion molecules that recruit monocytes to the arterial wall during atherogenesis. The inflammatory axis — NF-κB suppression in macrophages reducing TNF-α, IL-6, and MCP-1 secretion — reduces monocyte recruitment and foam cell formation in atherosclerotic plaques. LDL cholesterol reductions of 5-10% across GLP-1 trials are likely hepatic effects (GLP-1R modulation of hepatic LDLR expression) rather than primary mechanisms, but contribute to the overall atherogenic risk profile modification.

Men with total testosterone below 300 ng/dL have a 2-3 fold elevated cardiovascular event rate compared to eugonadal men — an association that survives adjustment for metabolic confounders in longitudinal cohort studies (Araujo et al., JCEM). The mechanistic basis involves direct androgen receptor (AR) signaling on vascular tissue: AR is expressed on endothelial cells and vascular smooth muscle cells, where testosterone binding promotes eNOS expression and activity (AR-mediated genomic upregulation of eNOS mRNA), reduces VCAM-1 and ICAM-1 expression, and attenuates vascular smooth muscle cell proliferation. In hypogonadal men, testosterone replacement reduces carotid intima-media thickness and improves endothelial function measures (FMD, pulse wave velocity) in RCTs — direct vascular evidence of androgen receptor-mediated vasoprotection. GLP-1's cardiovascular and hormonal mechanisms intersect at insulin resistance: insulin resistance drives SHBG suppression (increasing free T transiently but reducing total T via HPG suppression), increases aromatase activity (T→E2 in visceral adipose), and generates the pro-inflammatory cytokine milieu that independently suppresses LH. GLP-1-mediated insulin sensitivity restoration reverses each of these HPG-suppressive mechanisms, allowing testosterone recovery that then amplifies the vasoprotective effect through AR endothelial signaling. The additive EPA-GLP-1 mechanism: EPA (icosapentaenoic acid) at 4g/day (REDUCE-IT trial: HR 0.75 for MACE, n=8,179) works via membrane phospholipid incorporation displacing arachidonic acid from the eicosanoid pathway, reducing TXA2/PGI2 ratio and inflammatory eicosanoid production — a mechanism entirely non-overlapping with GLP-1R signaling and therefore additive in dual-agent cardiovascular risk reduction.